Japan’s pharmaceutical industry – the world’s third largest by market value after the United States and China – has long been associated with methodical development cycles and rigorous technical validation. But the sector is undergoing a gradual yet increasingly visible shift in how it evaluates external partners and drug development programmes.
Across therapeutics, particularly complex modalities such as peptides, the defining constraint is moving from scientific feasibility to execution speed.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
“The ‘how?’ has given way to the ‘how soon?’” explained Sharadsrikar Kotturi, chief scientific officer at Indian contract development and manufacturing organisation (CDMO) Neuland Laboratories, describing what he sees as a structural change in Japan’s engagement with global pharmaceutical partners.
Kotturi said the change was particularly visible at this year’s CPHI Japan forum, where conversations shifted from technical exploration to timelines, scalability and execution certainty. The evolving atmosphere was reflected even in the dress code, with ties and polished leather shoes increasingly replaced by sneakers and more casual attire – a visible sign of Japan’s business culture moving from highly formal, technology-centric discussions toward a more globally minded, pragmatic, cost- and deadline-driven approach.
For CDMOs, this shift is translating into earlier scrutiny of manufacturing reproducibility. Japan’s traditional pharma model has been characterised by long development horizons, detailed technical interrogation and a strong preference for internal validation.
That model is now being tested by a combination of external pressures: intensifying global competition, regulatory harmonisation across major markets, demographic strain linked to an ageing population, and mounting pressure to improve R&D productivity while controlling healthcare costs.
According to GlobalData analysis, Japan’s pharmaceutical market was worth an estimated ¥11.9 trillion in 2025 (approx. $76-83 billion), and is facing increasing economic and policy pressure. Regular drug price revisions, broader healthcare cost-containment measures and the expansion of generics are compressing returns on established portfolios, forcing manufacturers to reassess development timelines and operational efficiency.
Government targets to increase generic drug utilisation have accelerated consolidation among domestic manufacturers, while policymakers continue pushing for greater cost-effectiveness across the healthcare system.
Kotturi, who has engaged with Japanese pharmaceutical companies over nearly two decades, describes a clear change in the nature of technical dialogue.
“Ten years ago, discussions were dominated by mechanism and process understanding,” he said. “Today, the emphasis is increasingly on speed of delivery and cost certainty.”
While Japan retains a high level of scientific rigour, the decision-making lens is increasingly shaped by execution risk and time-to-market considerations. In practical terms, this is compressing evaluation cycles and shifting expectations from exploratory collaboration to delivery-focused partnerships.
According to Kotturi, this is also reflected in Japan’s growing reliance on external manufacturing and development capacity. Historically insular and self-contained, Japan is increasingly integrating into global outsourcing networks, particularly in Europe and India. However, the transition remains incremental.
“Outsourcing is becoming a requirement for survival for many Japanese companies,” Kotturi said, noting that procurement and qualification processes remain lengthy and conservative compared with Western biotech standards.
This structural pressure is reinforced by broader industry economics. Leading Japanese pharmaceutical groups are facing increasing pipeline replacement pressure as legacy products approach patent expiry, while cost inflation and drug pricing reforms are compressing returns on established portfolios.
Japanese pricing policy is also increasingly rewarding early product launches and multinational development participation, creating a system-level incentive for faster execution.
Against this backdrop, portfolio productivity and development velocity are becoming more prominent board-level priorities, particularly among large-cap Japanese pharma companies.
Peptides expose the execution bottleneck
The impact of this shift is visible in complex modalities such as peptide therapeutics. While demand is rising rapidly, particularly in metabolic and obesity-related indications, manufacturing execution remains challenging.
Kotturi identifies reproducibility as the central bottleneck. “Unlike small molecules, peptides are highly sensitive to batch-to-batch variation and impurity profiles,” he said. “The chemistry itself is straightforward. The challenge is controlling what else forms.”
Although peptide synthesis is based on established amide bond chemistry, increasing molecular length introduces multiple competing reaction pathways, making impurity control and scale-up consistency significantly more complex. This has exposed limitations in existing development frameworks that were largely designed for small-molecule systems.
“We are still using small-molecule frameworks to solve peptide problems. That gap remains a key constraint in scalable manufacturing.”
Reflecting growing demand for peptide manufacturing capacity, Neuland Laboratories is expanding its peptide infrastructure with a new laboratory in Hyderabad aimed at strengthening development and manufacturing capabilities for peptide-based therapeutics.
For Japanese firms, which place strong emphasis on validation, reproducibility challenges at scale heighten the importance of external partners with proven execution capability. This is reinforcing a gradual shift toward global CDMO collaboration, even as internal preferences for control and risk minimisation remain strong.
Supply chains and the “China plus one” recalibration
Alongside technical and operational pressures, Japan’s supply chain strategy is also evolving. Pharmaceutical manufacturers are increasingly reassessing exposure to China for key inputs, although full decoupling is widely regarded as impractical.
“There is a clear sense of strategic anxiety,” Kotturi said, reflecting concerns among Japanese counterparts about concentration risk rather than direct geopolitical confrontation.
This has accelerated diversification strategies often described as “China plus one,” with India and Vietnam emerging as alternative sourcing and manufacturing bases. At the same time, disruptions linked to broader geopolitical instability have reinforced the importance of supply chain resilience in Japanese procurement strategy.
Slow adaptation, structural change
Despite this gradual opening, Japan’s structural characteristics continue to shape the pace of change. Decision cycles remain long, partnerships require extensive validation, and technical scrutiny remains unusually deep even by global pharmaceutical standards.
Kotturi notes that this conservatism is both a constraint and a competitive strength. “They think in 50- to 100-year cycles,” he said. “That is both their strength and their constraint.”
Yet he also points to subtle but meaningful changes: increasing use of English in scientific forums, broader participation from international partners in conferences, and a growing willingness among Japanese firms to evaluate alternative manufacturing approaches.
The result is not disruption, but recalibration. Japan’s pharmaceutical sector is not abandoning its model of deep technical validation, but it is increasingly overlaying it with external expectations around speed, scalability and execution certainty.
For global CDMOs, this is reshaping engagement models with Japanese innovators. Where once the primary value proposition was technical depth, it is now increasingly combined with a requirement for predictable delivery timelines and industrial-scale reproducibility.
In that sense, the industry-wide shift from “how” to “how soon” is being absorbed into Japan’s pharmaceutical ecosystem not as a break from tradition, but as a gradual reweighting of priorities under global pressure.
